A. Konstantinova, V. Stroylov, D. Pozdyshev, M. Sova, S. A. Akbar, V. Muronetz, Yu. Stroylova, “Substituted cinnamides: Characterization of non-toxic inhibitors of alpha-synuclein aggregation”, Mendeleev Commun., 33:3 (2023), 334

Эта публикация цитируется в 2 статьях

Communications

Substituted cinnamides: Characterization of non-toxic inhibitors of alpha-synuclein aggregation

A. Konstantinova^a, V. Stroylov^bc, D. Pozdyshev^d, M. Sova^e, S. A. Akbar^f, V. Muronetz^d, Yu. Stroylova^dg

^a Department of Biotechnology, M.V. Lomonosov Moscow State University, Moscow, Russian Federation
^b N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
^c National Research University Higher School of Economics (HSE University), Moscow, Russian Federation
^d A.N. Belozersky Research Institute of Physico-Chemical Biology, M.V. Lomonosov Moscow State University, Moscow, Russian Federation
^e Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
^f Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran
^g Institute of Molecular Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation

Аннотация: Four substituted cinnamides were studied as potential inhibitors of alpha-synuclein aggregation. (E)-3-[3-(Benzo[d][1,3]dioxol-5-yl)acrylamido]benzoic acid (SMB11) was shown to inhibit amyloid fibril formation of recombinant human alpha-synuclein according to Congo Red and partial proteolysis by proteinase K assays. This compound and its analog with 3-trifluoromethylphenyl substituent demonstrated no cytotoxicity on human neuroblastoma SH-SY5Y cells.

Ключевые слова: alpha-synuclein, amyloid aggregation, cinnamides, surface docking, Parkinson’s disease.

Язык публикации: английский

DOI: 10.1016/j.mencom.2023.04.012